The API-to-ANDA Pharma Sweatshop That Builds Its Own Future

The Pharmaceutical Outsourcing Underdog That Acts Like it Runs the Game

Let’s talk about Caplin Point. You’ve never heard of them. Your doctor doesn’t know them. Your chemist definitely doesn’t have their branding on the wall. And that’s precisely the point.

Caplin is a CDMO (Contract Development and Manufacturing Organization) that makes injectable drugs, oral formulations, APIs, and sterile formulations for regulated markets. In normal human terms: when a pharma company (usually foreign) wants to sell a drug in America or Europe and doesn’t want to build their own factory, Caplin manufactures it. The company has 4,000+ global licenses, 650+ formulations across 36 therapeutic areas, and an asset-light model where it outsources 45% of production while running the other 55% in-house across 10 manufacturing facilities in India.

The twist? Over 82% of revenues come from Latin America (generics and branded generics). They’re now pivoting aggressively into the US regulated market through their Caplin Steriles subsidiary — and they’re doing it profitably. Q3 FY26: ₹543 crore revenue, ₹164 crore profit, 35% operating margins, and near-zero debt. The stock has tanked 14% in three months anyway. Welcome to the market.

In February 2026, they picked up 10 additional FDA-approved ANDAs (Abbreviated New Drug Applications) for ~$50+ million upfront. They’re building a $100+ crore manufacturing facility in Mexico. They just started exhibit batches for an oncology injectable facility. And they’re hiring people who used to inspect them to make sure they don’t disappoint the FDA. This is a company that’s building its own empire while paying single-digit dividend yields.

Outsourcing Done Right. Or At Least, Done Profitably.

Caplin operates the textbook CDMO playbook: a pharma company calls them up, hands them a drug molecule, says “make 10 million vials,” and Caplin builds the factory (or uses one of theirs), runs the batches, handles FDA compliance, and delivers the goods. No brand. No marketing. No CEO Instagram posts about disruption. Just execution.

The business is split into two halves: (a) Latin America (82% of revenue) where they’re established market leaders in generics and branded generics, selling through a 30,000+ distribution network; and (b) Regulated Markets (growing rapidly) where Caplin Steriles USA is building direct-to-customer distribution, launching 14 products so far and clocking nearly $10 million in revenue from their own label in its first year — without cutting prices or taking shortcuts.

The company operates on an asset-light model: 45% outsourced from partners in India and China, 55% manufactured in-house across 10 facilities in India (Tamil Nadu, AP, Telangana). This means they can scale without massive capex, except… they’re spending ₹1,000 crore over three years anyway because the US opportunity is that big. The margin profile is ridiculous: 35% operating margins, 28.5% net profit margins, and they’re reinvesting 100% of those profits into growth.

Q3 FY26: The Numbers That Make No Sense in a Down Market